Apellis Pharmaceuticals Inc. (APLS), Thursday, announced that it expects the European Medicines Agency's Committee for Medicinal Products for Human Use, or CHMP, to adopt a negative opinion on the authorization application of intravitreal Pegcetacoplan.
Apellis Announces Seven Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
WALTHAM, Mass., Sept. 30, 2022 Apellis Pharmaceuticals, Inc. , a global biopharmaceutical company and leader in complement, today announced that four oral presentations of data from the Phase 3. | September 30, 2022
Apellis to Showcase Leadership in Retina at Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
Nachrichtenquelle: globenewswire | 16.04.2021, 18:44 | 82
10 accepted abstracts include five oral presentations from pioneering artificial intelligence (AI) collaboration
Presentations support the potential of intravitreal pegcetacoplan, an investigational targeted C3 therapy, as the first treatment for geographic atrophy (GA) WALTHAM, Mass., April 16, 2021 (GLOBE NEWSWIRE)
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that 10 abstracts were accepted for presentation at the virtual Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting to be held May 1-7, 2021. These abstracts feature a breadth of data, from presentations that demonstrate the